The Neuroscience of Pain: Why Some People Feel More Than Others

Pain Sensitivity Genetics: Your DNA Sets a Baseline

A 2025 UK Biobank study of over 134,000 people found that approximately 9.8% of the variance in chronic pain intensity can be attributed to common genetic variants.^[s] That number may sound modest, but it represents a solid, measurable genetic foundation underlying something as subjective as pain.

Pain sensitivity genetics research goes beyond single-gene effects. Twin and family studies paint an even broader picture. Depending on the pain type and study design, heritability estimates range from 7% to 59%.^[s] The wide range reflects pain’s complexity: headaches, back pain, and fibromyalgia each have different genetic architectures. But the core finding holds: genetics matter.

A recent GWAS meta-analysis identified 343 independent genetic loci associated with multisite chronic pain, including 92 novel signals found through meta-analysis.^[s] These aren’t single “pain genes” in the simple sense; they represent a polygenic architecture where hundreds of small-effect variants combine to shift your pain sensitivity up or down.

The Brain’s Individual Pain Signature

A Nature Neuroscience study in 2026 revealed something striking in two people with chronic pain: personalized brain signatures for spontaneous pain did not generalize between the participants.^[s] The researchers built personalized decoding models using fMRI that accurately tracked fluctuations in spontaneous pain intensity in those individuals, but each model relied on individually unique brain features.

This small-N finding has profound implications. It suggests that the neural basis of spontaneous chronic pain may not reduce to a single broken circuit common to all sufferers. Instead, each person’s pain experience may emerge from their own particular brain configuration. As the researchers noted, “functional magnetic resonance imaging can assess spontaneous pain, highlighting the need for precise, patient-specific approaches.”^[s]

Brain structure also plays a role. The UK Biobank genetic study found the strongest genetic correlation for pain intensity was with grey matter volume of the right insular cortex.^[s] The insula processes bodily sensations including pain, and its size appears genetically linked to how intensely you experience them.

Two Circuits: Why Chronic Pain Is Different

Stanford researchers reported a mouse-circuit discovery in 2026 that challenges how we think about pain: acute pain and chronic pain can be separable. “A surprise to us was that acute pain and chronic pain can be completely separate,” said senior author Xiaoke Chen. “There is a dedicated circuit that only activates after injury, which gives us the opportunity to target the chronic pain component but leave protective acute pain intact.”^[s]

In the mouse study, the chronic pain circuit ran from the spinal cord through the thalamus to the cortex, then to the brainstem, and back to the spinal cord. When researchers silenced this circuit in mice, chronic pain subsided while acute pain responses remained intact. Even more telling: “Just activating these neurons is enough to induce a chronic pain state.”^[s]

This explains a hallmark of chronic pain: sensitization, where the brain misinterprets ordinary touch as painful.^[s] In those mouse models, the dedicated chronic circuit, once activated, could sustain pain sensitivity independently of any ongoing injury. Individual variation in comparable circuits may help explain why some people develop chronic pain after injury while most recover.

Why Women Experience More Pain

Women consistently report lower pain thresholds, greater pain unpleasantness, and higher rates of chronic pain conditions than men.^[s] The difference is not merely psychological; biological mechanisms are part of it.

A 2026 NIH summary of mouse and human data reported that male sex hormones were associated with higher levels of an anti-inflammatory molecule called interleukin-10 in the skin. Males with more IL-10-producing monocytes recovered from pain faster.^[s] This sex hormone-immune link may help explain why women are more susceptible to developing chronic pain after injury, adding a critical dimension to pain sensitivity genetics.

The immune mechanisms driving neuropathic pain also differ by sex. In males, pain is predominantly driven by microglia-dependent neuroinflammation. In females, it is sustained by adaptive immune mechanisms involving T-cell signalling.^[s] This isn’t a minor detail; it suggests pain treatments that work for men may not work for women, and vice versa.

The Spinal Cord’s Overlooked Role

Pain research has focused heavily on the brain, but the spinal cord plays a critical gating role. A 2025 Nature Communications study developed what they called a “corticospinal pain sensitivity signature,” a pattern of connectivity between brain and cervical spinal cord that predicts individual pain sensitivity.^[s]

The researchers went further, using transcranial magnetic stimulation to test causality. Enhanced motor cortex-to-spinal connectivity directly changed pain perception in their subjects.^[s] This corticospinal biomarker outperformed brain-only models in predicting who would be sensitive to pain, suggesting pain sensitivity biology extends beyond brain-only models.

Why Placebos Work for Some People

Placebo analgesia varies dramatically between individuals, and brain imaging explains why. A large 2024 study found that placebo treatment caused robust pain relief, but did not decrease activity in brain regions linked to nociceptive pain processing.^[s]

Instead, placebos worked through cognitive and affective brain systems, particularly regions related to motivation and value. Individual differences in placebo response correlated with neural changes in these systems.^[s] People whose cognitive and motivational systems shift more during placebo treatment tend to show more behavioral analgesia. This connects to how brain decisions precede conscious awareness; expectation can change pain through brain systems outside simple conscious willpower.

Epigenetics: Your Life Rewrites Your Pain Genes

Your DNA sequence sets a baseline, but epigenetic modifications can dial pain sensitivity up or down over your lifetime. A 2026 study of fibromyalgia and chronic fatigue patients found significantly elevated methylation of the OPRM1 gene promoter, which codes for the mu-opioid receptor.^[s]

This epigenetic silencing may impair the body’s natural pain-relief system. The elevated methylation persisted even after controlling for symptom severity, supporting “the hypothesis of dysregulated opioidergic signaling in these conditions.”^[s]

Long-term analgesic use is also associated with epigenetic differences. A 2026 study found distinct DNA methylation signatures near nociception-relevant genes for different drug classes: 12 differentially methylated regions for antidepressants, 8 for gabapentinoids, 6 for NSAIDs, 5 for opioids, and 2 for acetaminophen.^[s] Analgesic exposure may be linked to changes in the pain-relevant epigenome, much like brain chemistry and addiction interact in ways that persist beyond initial exposure.

The Affective Dimension: Why Pain Feels Bad

Pain has two components: the sensory intensity and the unpleasantness. A 2026 Nature study identified specific neurons in the anterior cingulate cortex that encode the affective-motivational dimension of pain, the suffering component.^[s]

These neurons are selectively modulated by opioids. Morphine “reduced affective-motivational behaviours without altering sensory detection or reflexive responses, mirroring how opioids alleviate pain unpleasantness in humans.”^[s] This helps explain why opioids can reduce pain unpleasantness without necessarily altering sensory detection.

Variation in these cingulate circuits may explain why some people cope well with chronic pain while others find identical levels of sensory input unbearable. The neuroscience of emotional distress maps onto pain because affective pain processing overlaps with broader emotional-distress circuitry.

Pain Sensitivity Genetics and Prediction

Machine learning models can now predict individual pain sensitivity from brain scans with modest but reliable accuracy. A 2025 study across 1,046 participants developed a model that predicted pain sensitivity across different pain types, including heat, contact heat, and mechanical pain.^[s]

More practically, the same model predicted analgesic treatment effects in healthy volunteers.^[s] This opens a research path toward personalized pain medicine where treatment selection is guided by brain imaging rather than trial and error.

The Complexity Caveat

Despite progress, pain sensitivity genetics remains fiendishly complex. A 2025 systematic review examined whether common genetic variants affect conditioned pain modulation, an objective test of pain inhibition capacity. The finding: “For now, it seems that dynamic experimental pain measurements are robust to genetic and epigenetic variations.”^[s]

This doesn’t mean genetics are irrelevant; it means the pathways linking specific genes to specific pain responses remain hard to pin down. Pain sensitivity genetics operates through hundreds of small effects, developmental trajectories, gene-environment interactions, and epigenetic modifications that accumulate over a lifetime.

What This Means

Pain sensitivity genetics research validates what chronic pain patients have long insisted: their pain is real, biological, and not imagined. The variation in how people experience pain reflects genuine differences in neural circuitry, immune function, and genetic architecture shaped by pain sensitivity genetics.

The clinical implications are substantial. Sex-specific pain mechanisms suggest treatments should be developed and tested differently for men and women. The discovery of a dedicated chronic pain circuit offers a target for therapies that could relieve persistent pain without eliminating the protective acute pain response. Epigenetic markers may eventually identify patients at risk for developing chronic pain before it becomes entrenched.

The science confirms that pain is personal. Your experience of a stubbed toe, a migraine, or a surgical recovery is shaped by your particular genes, your brain’s unique connectivity patterns, your sex, your immune system, and your life history written into your epigenome. Understanding how your brain models other people‘s pain begins with accepting that their experience may be fundamentally different from yours.

Pain Sensitivity Genetics: Polygenic Architecture and Heritability

Quantitative genetic analysis of chronic pain intensity in a UK Biobank cohort of 134,627 individuals yielded an SNP-based heritability estimate of 0.098 ± 0.005, indicating that approximately 9.8% of variance in chronic pain intensity is attributable to common genetic variants.^[s] This represents the lower bound; twin and family studies estimate broader heritability between 7% and 59% depending on phenotype definition and study design.^[s]

The polygenic architecture is increasingly well-characterized. GWAS meta-analysis has identified 343 independent genetic loci associated with multisite chronic pain, including 92 novel signals beyond the initial 76 loci identified in earlier UK Biobank analysis.^[s] The genetic signal is heavily enriched in brain-expressed transcripts, with Cauchy p = 1.32 × 10⁻⁶ for brain-specific transcriptional programs, ranking first among all annotated tissues.^[s]

The strongest genetic correlation was observed for grey matter volume of the right insular cortex (rg = −0.158, p = 2.34 × 10⁻⁷).^[s] Mediation analyses suggested that insula-related imaging measures partially mediated polygenic effects on pain intensity; Mendelian randomization separately linked lower right insula volume with higher chronic pain intensity.

Personalized Brain Decoding: Individually Unique Pain Signatures

A Nature Neuroscience precision fMRI study in two individuals with chronic pain demonstrated individually unique brain signatures for spontaneous pain that did not generalize between participants.^[s] Personalized decoding models achieved prediction-outcome correlations of r = 0.40-0.61 for tracking fluctuations in spontaneous pain intensity across sessions, runs, and minutes, but “each model relied on individually unique brain features and did not generalize across participants.”^[s]

This finding has methodological implications for pain neuroimaging. Group-level analyses may obscure clinically relevant individual variation. The researchers concluded that “functional magnetic resonance imaging can assess spontaneous pain, highlighting the need for precise, patient-specific approaches.”^[s]

Complementary EEG work across 633 participants found that neural variability, rather than average amplitude, “is a replicable and potentially preferential indicator of individual differences in pain intensity discriminability.”^[s] Variability and amplitude were mutually independent, with distinct temporal and oscillatory profiles.

Dedicated Chronic Pain Circuitry: The Spinal-Thalamo-Cortico-Brainstem Loop

Stanford researchers identified a mouse neural circuit specific to chronic pain, originating in the spinal cord, projecting to the thalamus, then to cortex, to brainstem (including the rostral ventromedial medulla), and back to the spinal cord. Chemogenetic silencing of this circuit relieved chronic pain while preserving acute pain responses in mice.^[s]

The finding that “acute pain and chronic pain can be completely separate” has therapeutic implications: targeting the dedicated chronic circuit could relieve persistent pain without eliminating protective nociception.^[s] Critically, chemogenetic activation of this circuit in healthy mice was sufficient to induce a chronic pain state: “Just activating these neurons is enough to induce a chronic pain state.”^[s]

In the mouse study, this circuit mediated the phenomenon of sensitization, where “the brain misinterprets touch to be a painful stimulus.”^[s] Individual variation in comparable circuit thresholds may help explain differential vulnerability to chronic pain development post-injury.

Sex-Specific Neuroimmune Mechanisms

Sex differences in pain involve biological mechanisms as well as sociocultural factors. Women consistently exhibit lower pain thresholds, more unpleasantness, and higher prevalence of chronic pain syndromes.^[s]

The neuroimmune mechanisms differ fundamentally by sex. “Neuropathic pain in males is predominantly driven by microglia-dependent neuroinflammation, whereas in females it is sustained by adaptive immune mechanisms involving T-cell signalling.”^[s] This dual-pathway model suggests sex-stratified treatment approaches, a critical consideration for pain sensitivity genetics research.

An NIH summary of a Science Immunology study reported a mechanism that may underlie faster pain resolution in males: “Males had higher levels of an anti-inflammatory molecule called interleukin-10 (IL-10) in their skin than females. The more of those cells they had, the faster they recovered from pain.”^[s] In mouse experiments, sex hormones were implicated: “Male sex hormones were associated with higher IL-10 levels and faster pain recovery.”^[s]

Corticospinal Connectivity: Beyond Brain-Centric Models

Conventional pain neuroimaging has overlooked the spinal cord’s hub role in pain gating. A 2025 Nature Communications study using simultaneous corticospinal fMRI developed a “corticospinal pain sensitivity signature, a pattern of functional connectivity from simultaneous corticospinal magnetic resonance imaging, predicts individual pain sensitivity and clinical pain.”^[s]

Validated across 723 healthy and 46 patient participants, the corticospinal model outperformed brain-only models. Crucially, “transcranial magnetic stimulation perturbation revealed a causal axis where enhanced motor cortex-spinal connectivity directly changes pain perception (r = 0.55).”^[s] This supports a causal role for the motor cortex-spinal axis in pain sensitivity, a key finding for pain sensitivity research.

Placebo Mechanisms: Cognitive-Affective vs. Nociceptive Pathways

A pre-registered fMRI study (N=392) dissociated placebo mechanisms: “Placebo treatment caused robust analgesia in conditioned thermal pain that generalized to unconditioned mechanical pain. However, placebo did not decrease pain-related fMRI activity in brain measures linked to nociceptive pain.”^[s]

Placebo instead reduced activity in the Stimulus Intensity Independent Pain Signature (SIIPS), a neuromarker of higher-level contributions to pain, and affected motivational brain regions. “Individual differences in behavioral analgesia were correlated with neural changes in both modalities.”^[s] This helps explain inter-individual placebo response variability and connects to how brain processes can precede conscious awareness of relief.

Epigenetic Dysregulation: OPRM1 Methylation and Analgesic Remodeling

Epigenetic modifications alter pain sensitivity genetics expression. A case-control study found fibromyalgia and ME/CFS patients exhibited significantly elevated OPRM1 promoter methylation: “Patients showed significantly higher OPRM1 promoter methylation, which remained after adjusting for symptom severity and QST findings.”^[s]

The OPRM1 gene encodes the mu-opioid receptor. Hypermethylation likely silences expression, impairing endogenous opioid analgesia. “Increased OPRM1 methylation in patients, independent of symptoms or pain sensitivity measures, supports the hypothesis of dysregulated opioidergic signaling in these conditions.”^[s]

Analgesic medication use is associated with epigenetic differences. A Quebec Pain Registry EWAS (N=430) found genome-wide significant differentially methylated regions for each drug class: “2 for acetaminophen, 8 for gabapentinoids, 6 for NSAIDs, 5 for opioids, and 12 for antidepressants.”^[s] Sex-stratified patterns emerged, suggesting analgesic drug exposure may be linked to different pain-relevant epigenomic patterns across individuals, paralleling how brain chemistry and addiction interact.

Anterior Cingulate Cortex: The Neural Basis of Pain Unpleasantness

A Nature study mapped the cortical encoding of pain affect: “a population of cingulate neurons encodes spontaneous pain-related behaviours and is selectively modulated by morphine.”^[s] These mu-opioid receptor-expressing neurons in the anterior cingulate cortex encode the affective-motivational dimension of pain.

“Morphine reversed these neuropathic neural dynamics and reduced affective-motivational behaviours without altering sensory detection or reflexive responses, mirroring how opioids alleviate pain unpleasantness in humans.”^[s] A chemogenetic gene therapy targeting these cells mimicked opioid analgesia in mouse neuropathic pain, suggesting a possible way to reduce systemic opioid risks.

This dissociates the sensory and affective pain dimensions at the circuit level. Individual variation in cingulate circuitry may explain why pain of equivalent sensory intensity produces different suffering levels. The neuroscience of emotional distress overlaps with affective pain processing in these circuits.

Cortico-Thalamic Amplification: The Insular Pathway

Research using optogenetics and chemogenetics in mice identified a glutamatergic pathway from the deep insular cortex to the rostral central medial thalamic nucleus that contributes to both pain sensitivity and anxiety-like behavior. “Collectively, these findings identify the dlICVGluT2-rCMCaMKIIα pathway as a contributor to pain-anxiety comorbidity in mice.”^[s]

In those experiments, activation of this pathway lowered mechanical and thermal pain thresholds while simultaneously evoking anxiety-like behaviors, providing mechanistic evidence for central sensitization and the frequent comorbidity of chronic pain with anxiety disorders.

Machine Learning Prediction: Toward Personalized Pain Medicine

A multi-dataset fMRI study (N=1,046 across 6 datasets) demonstrated that “a machine learning model is developed that accurately predicts not only pain sensitivity (r = 0.20∼0.56, ps < 0.05) but also analgesic effects of different treatments in healthy individuals (r = 0.17∼0.25, ps < 0.05)."^[s]

The study established sample size requirements: >200 participants for univariate whole-brain correlation analysis, >150 for multivariate machine learning modeling. This benchmark enables future biomarker development informed by pain sensitivity genetics.

Limitations: Genetic Robustness of Pain Modulation Tests

Not all pain phenotypes show clear genetic associations. A 2025 systematic review of conditioned pain modulation tests found low-quality evidence that common genetic variants in COMT, SLC6A4, and OPRM1 do not significantly alter results: “For now, it seems that dynamic experimental pain measurements are robust to genetic and epigenetic variations.”^[s]

This suggests pain sensitivity genetics operates through mechanisms not fully captured by standard pain modulation tests, likely involving developmental trajectories, gene-gene interactions, and gene-environment interactions that accumulate over the lifespan.

Clinical Implications

Pain sensitivity genetics research establishes biological validity for individual variation in pain experience. The dedicated chronic pain circuit offers a therapeutic target distinct from acute pain pathways. Sex-specific neuroimmune mechanisms demand sex-stratified treatment development. Epigenetic markers may identify patients at risk for chronic pain development, and machine learning models may guide personalized analgesic selection.

Understanding how your brain models other people‘s pain requires accepting that their neural architecture, genetic variants, immune profiles, and epigenetic history create genuinely different experiences from yours. The science supports this clinical intuition with mechanistic detail.